Wilson病患者门静脉高压及其预后意义
这项回顾性研究纳入137例Wilson病患者(Leipzig评分≥4),中位随访9.0年,49例(35.8%)出现临床显著门静脉高压(CSPH)特征;有CSPH特征者10年代偿事件更多、无移植生存更差,肝硬度<15 kPa且血小板正常(≥150 G/L)者预后较好。
要点
- 137例Wilson病患者中49例(35.8%)出现CSPH特征,3例(2.2%)发生急性静脉曲张出血。
- 有CSPH特征的代偿期患者10年代偿事件8.3% vs 无CSPH者1.5%(p=0.3),无移植生存91.7% vs 98.6%。
- 肝硬度<15 kPa且血小板≥150 G/L者10年代偿事件2.6% vs 8.4%(p=0.002),无移植生存97.7% vs 83.9%(p=0.006)。
核心结论
- 出现CSPH特征的Wilson病患者肝代偿事件和肝相关死亡风险增加,需要定期筛查并及时启动有效的CSPH针对性治疗。
研究设计与样本
- 回顾性研究,纳入137例Wilson病患者(Leipzig评分≥4),在维也纳总医院随访,中位观察期9.0(3.9-17.7)年。
主要发现
- 49例(35.8%)出现CSPH特征:静脉曲张14例(10.2%)、脾大40例(29.2%)、腹水20例(14.6%)、肝性脑病18例(13.1%)、急性静脉曲张出血3例(2.2%)。
- 共8例(5.8%)死亡,其中3例死亡由CSPH相关并发症导致。
- 10年内有CSPH特征的代偿期患者代偿事件为8.3% vs 无CSPH者1.5%(p=0.3),无移植生存为91.7% vs 98.6%。
- 发生肝代偿事件的患者10年无移植生存进一步降至26.7%(log-rank p<0.0001)。
- 肝硬度<15 kPa且血小板正常(≥150 G/L)者10年代偿事件为2.6% vs 8.4%(p=0.002),10年无移植生存为97.7% vs 83.9%(p=0.006)。
临床怎么用
- 作者认为,出现CSPH特征的Wilson病患者肝代偿事件和肝相关死亡风险增加,需要定期筛查并及时启动有效的CSPH针对性治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Wilson's disease may progress to cirrhosis and clinically significant portal hypertension (CSPH). We aimed to assess the prevalence and prognostic impact of CSPH-related features on hepatic decompensation and transplant-free survival in patients with Wilson's disease. METHODS AND RESULTS: About 137 patients with Wilson's disease (Leipzig score ≥4), followed for a median observation period of 9.0 (3.9-17.7) years at the Vienna General Hospital, were included in this retrospective study. Overall, 49 (35.8%) developed features of CSPH: 14 (10.2%) varices, 40 (29.2%) splenomegaly, 20 (14.6%) ascites, 18 (13.1%) hepatic encephalopathy and 3 (2.2%) experienced acute variceal bleeding. Overall, 8 (5.8%) patients died, including three deaths caused by CSPH-related complications. Within 10 years, compensated patients with features of CSPH developed more decompensation events (8.3% vs. 1.5% in patients without CSPH, p = 0.3) and had worse transplant-free-survival (91.7% vs. 98.6%), which further declined in patients with hepatic decompensation (26.7%, log-rank: p < 0.0001). Patients with liver stiffness <15 kPa and normal platelets (≥150 G/L) were less likely to decompensate within 10 years (2.6% vs. 8.4%, p = 0.002) and had a better 10-year transplant-free-survival (97.7% vs. 83.9%, p = 0.006). CONCLUSIONS: Patients with Wilson's disease developing features of CSPH are at an increased risk for hepatic decompensation and liver-related mortality, warranting for regular screening and timely initiation of effective CSPH-directed treatments.
引用
- Burghart L, Ferenci P, Petrenko O, et al. Portal hypertension and its prognostic implications in patients with Wilson's disease. Aliment Pharmacol Ther. 2024. PMID: 38798050. doi:10.1111/apt.18060
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。